DCISionRT - DCIS Management Test
Predicts radiation benefit. DCISionRT is the only test capable of predicting an individual patient’s benefit from radiation therapy. Using DCISionRT provides you with 10-year Total and Invasive Recurrence Risk after breast conserving surgery as well as surgery with radiation therapy. No other test can do this.
Enables precision medicine.
DCISionRT provides you the information to deliver precision medicine to your patients. Unlike grade, tumor size or patient age, DCISionRT quantifies a woman’s risk based on her DCIS biology. Studies have shown that DCISionRT reclassifies over 50% of patients compared to grade and size[REF CCR]. The future of DCIS management is here with DCISionRT.
Unmatched clinical evidence.
DCISionRT has undergone multiple independent validations, including the landmark SweDCIS randomized clinical trial. The test has the highest dynamic range and most consistent results study to study. Evidence includes over 2000 patients from development through validation. No other DCIS test is supported by published Level 1b clinical evidence.
Traditional Clin/Path Reclassified by DCISionRT
In a multisite study including 474 DCIS patients, DCISionRT substantially reclassified DCIS patient risk compared to traditional clinicopathologic risk assessment, such as grade (shown). In fact, 53% of patients with low or intermediate grade DCIS (grade 1 or 2) were upstaged to elevated risk by DCISionRT and 30% of patients with high grade DCIS (grade 3) were identified as low risk by DCISionRT1. With DCISionRT, patients and physicians have access to a test that enables truly personalized treatment based on a patient’s individual biology.
10 Year Total Recurrence Risk Traditional Clin/Path vs DCISionRT
Traditional risk assessment using DCIS grade to DCISionRT risk groups indicates the power of the DCISionScore. While traditional risk assessment with DCIS grade shows little difference for low/intermediate grade DCIS (grade 1 & 2) compared to high grade DCIS, DCISionRT distinguishes which patients have a clinically low risk (DCISionScore ≤3) from those with clinically elevated risk (DCISionScore >3). With DCISionRT, Know Your Risk.
Results are shown are for the 196 patients treated with conserving surgery treated patients with clear margins in a multisite study. Total recurrence risks shown are adjusted for year of diagnosis. This was demonstrated in a multisite study of 474 patients1.
1 Bremer T, Whitworth P, Patel R, et al. . A biologic signature for breast ductal carcinoma in situ to predict radiation therapy (RT) benefit and assess recurrence risk. Clin Cancer Res . 2018; doi:10.1158/1078-0432.CCR-18-0842.
In an independent clinical validation of DCISionRT in the landmark SweDCIS randomized clinical trial, patients with low Decision Scores no significant invasive risk reduction from radiation therapy after surgery whereas patients with elevated Decision Scores had a 9% reduction in invasive risk (HR 0.24, p=0.012). This study, for the first time, demonstrates a DCIS test that predicts the extent to which patients benefit from radiation therapy.